comscoreThe Importance of Diversity in Breast Cancer Clinical Trials

The Importance of Diversity in Breast Cancer Clinical Trials

Dr. Lola Fayanju talks about the importance of making clinical trials more diverse.
Sep 15, 2021

Studies show that overall participation in cancer clinical trials is low, and participation by people of color is even lower. This is thought to be part of the reason that minority women — especially Black women — have worse breast cancer outcomes than white women.

One strategy to help reduce disparities in breast cancer outcomes is to make clinical trials more diverse.

Listen to the podcast to hear Dr. Lola Fayanju explain:

  • why diversity in clinical trials is important

  • some of the barriers that keep people of color from enrolling in clinical trials and how they can be overcome

  • how she talks to all her patients about clinical trials

About the guest
Lola Fayanju headshot
Oluwadamilola "Lola" Fayanju, MD, MA, MPHS, FACS

Dr. Fayanju is the Helen O. Dickens Presidential Associate Professor and chief of breast surgery at Penn Medicine, the University of Pennsylvania Health System in Philadelphia, PA

— Last updated on June 29, 2022, 2:49 PM

Support to produce more content like this

Your donation goes directly to what you read, hear, and see on